How Psilocybin Can Rewire Our Brain, Its Therapeutic Benefits & Its Risks

Huberman opens by defining the subject precisely: psilocybin is a psychedelic, meaning it alters the psyche and therefore the level of consciousness, changing how a person perceives the external world and the internal one — memories, thoughts, feelings — and, crucially, continuing to change them long after the compound has cleared. That persistence, rather than the acute experience, is what has generated clinical interest in depression, alcohol use disorder, addictions, OCD and eating disorders. He also sets the legal frame early: as of May 2023 psilocybin remains a Schedule I substance in the United States, with Oregon's regulated therapeutic programme and a handful of decriminalised municipalities as narrow exceptions. The framing matters because the rest of the episode describes mechanisms and trial results that are not available to a listener outside a clinical or research setting.

The central claim is deliberately counter-intuitive: psilocybin basically is serotonin. It mimics serotonin, but does so selectively and with unusual force, activating a subset of serotonin receptors strongly enough to trigger plasticity in the circuits that serve memory and perception. The active compound, he notes, is not psilocybin itself but psilocin, into which psilocybin is converted; that conversion step governs both the duration of the journey and the length of the plasticity window that follows it. This is the thread the episode keeps returning to: most of the durable benefit appears to accrue after the session, in the period when the acute perceptual effects have faded.

He is careful to separate plasticity from therapy. Neuroplasticity is not automatically therapeutic; to be therapeutic it must be adaptive, leaving the person functioning better than before. Whether a given journey is adaptive depends on conditions that are under human control — eyes open or closed, whether music is played and of what kind, dosage — which is why he spends the bulk of the episode on protocol rather than on pharmacology alone. The same caution applies to the legal and clinical frame: possession and sale remain unlawful outside narrow exceptions, and the therapeutic claims he goes on to describe belong to supervised research settings.

The puzzle Huberman poses is this: if psilocybin looks so much like serotonin, why does it produce a circumscribed set of effects — visual and auditory hallucinations, particular thought patterns, and, in the clinic, mood improvement — rather than the diffuse effects of serotonin itself? The answer is receptor selectivity. Psilocybin binds and activates mainly the serotonin 2A receptor, which is expressed in specific brain regions and even on specific parts of neurons, and that localisation is what converts a serotonin-like molecule into a circuit-specific intervention.